-

Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field and in-process testing applications requiring qualitative to semi-quantitative test results.

This portable instrument is a highly flexible, easy to use and accurate imaging platform used for lateral flow assay analysis. RapidScan ST5-W is unique to the market with its flexibility, multiple target analysis and its compatibility with applications for Eurofins Technologies’ allergen, GMO, glyphosate and algal toxins lateral flow tests. The reader performs well both in laboratories and in field testing environments, where quick results are needed for contamination analysis. With a data storage capacity of up to 5000 test results, reports are easy to create and export.

A wide range of Eurofins Technologies’ rapid test applications are already validated on the RapidScan reader, including gluten (allergen), corn, soybean and canola (GMO), glyphosate (pesticide) and algal toxins (toxins in drinking and fresh water) lateral flow assays. Further test validations will follow in 2022, including more than 20 allergens and additional GMO rapid testing capability.

This new reader will play an instrumental role in Eurofins Technologies’ mission to provide an integrated solution to its food and water safety customers. The reader provides a reliable and quick way to test for multiple contaminations with high-quality lateral flow devices and obtain and analyse results with a single reader platform at any environment and within just a few minutes.

About Eurofins Technologies

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative methods and applications. For further information, please visit the Eurofins Technologies website.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

For more information: http://www.eurofins-technologies.com/
Dr. Gábor Kohut
Eurofins Technologies
GaborKohut@eurofins.com

Eurofins

BOURSE:ERF


Contacts

For more information: http://www.eurofins-technologies.com/
Dr. Gábor Kohut
Eurofins Technologies
GaborKohut@eurofins.com

More News From Eurofins

Eurofins MET Laboratories Opens New Safety, EMC, Wireless, and Renewable Energy Laboratory in the Boston Tech Corridor

BOSTON--(BUSINESS WIRE)--Eurofins MET Laboratories, part of the Eurofins Electrical & Electronics global network, announces the opening of its new state-of-the-art 60,000-square-foot testing laboratory in Littleton, Massachusetts – a prime location in the Boston innovation corridor. Positioned at the epicenter of New England's med-tech, wireless innovation, clean energy, and advanced electronics ecosystem, the capabilities of this laboratory further position Eurofins MET Laboratories as the...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 26th January to 30th January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/01/2026 FR0014000MR3 5 000 70.7336 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 27/01/2026 FR0014000MR3 5 000 70.9680 XPAR EUROFINS SCIENTIFIC 529900JEHFM47...

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...
Back to Newsroom